Search results
Results from the WOW.Com Content Network
Treatment involves stopping the associated statin medication and taking medication to suppress the immune system. SAAM is estimated to occur in 2-3 people out of every 100,000 statin-treated individuals. It appears to be more common in people over the age of 50. [3]
This is a partial list of herbs and herbal treatments with known or suspected adverse effects, either alone or in interaction with other herbs or drugs.Non-inclusion of an herb in this list does not imply that it is free of adverse effects.
Statins remain a first-line treatment in familial hypercholesterolemia, [54] although other cholesterol-reducing measures may be required. [56] In people with homozygous deficiencies, statins may still prove helpful, albeit at high doses and in combination with other cholesterol-reducing medications.
Statins are one of the most commonly prescribed drugs in the UK, with millions taking them to cut their chance of a heart attack or stroke. Stopping statin treatment early ‘could reduce ...
Cafestol is a natural compound found in unfiltered coffee that may benefit certain aspects of metabolic health. New research suggests that 6 milligrams of cafestol twice daily for 12 weeks might ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
[66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66] Risk factors for statin induced rhabdomyolysis include older age, renal impairment, high dose statins and use of medications that reduce the breakdown ...
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88; NADPH-dependent, EC 1.1.1.34) of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids.